Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP OKs Project Team Proposal to Boost Pharma Innovation, Create Command Tower
The ruling Liberal Democratic Party (LDP) on May 30 approved a proposal compiled by its project team on pharmaceutical innovation, which embraces a call for the creation of a “command tower” function to oversee the industry. The proposal was adopted…
To read the full story
Related Article
- LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
- LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
May 22, 2024
- LDP Project Team Submits Proposal to Prime Minister
June 5, 2023
- LDP Project Team to Finalize Pharma Policy Proposal for Honebuto by May-End, Submit It to Prime Minister
May 17, 2023
- Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
May 17, 2023
- Wholesaler Lobby Raps Politicians over Product Coverage of Off-Year Cuts
April 18, 2023
- LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
- LDP Project Team Calls for Price Maintenance During Patent Period and Rethink of Off-Year Cuts
April 11, 2023
REGULATORY
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…